ChrysaLabs, founded in 2017 and based in Montreal, Canada, specializes in the development of innovative technology for real-time soil fertility assessment. The company offers a portable probe that accurately measures soil nutrients and health directly in the field, allowing producers and agronomists to make informed decisions regarding fertilizer management. This advanced optical technology evaluates soil properties at various depths and requires no prior preparation, facilitating immediate access to critical data. In addition to the probe, ChrysaLabs provides a management platform that enables users to access this information and take appropriate actions to optimize crop yield and soil health.
Capstan Therapeutics is advancing precision in vivo cell engineering to develop therapeutics for a broad range of disease categories with unmet or underserved clinical need.
ReCode Therapeutics is a development-stage biopharmaceutical company focused on the correction of the nonsense mutations that account for 1/3 of all inherited diseases, including approximately 10% of cystic fibrosis. They have combined selected tRNAs with their unique and diverse proprietary delivery platforms to create and develop first-in-class suppressor tRNA-nanoparticle therapeutics for correcting nonsense mutations. ReCode’s diverse pipeline includes lead programs for primary ciliary dyskinesia (PCD) and nonsense mutations in cystic fibrosis (CF). The company’s proprietary non-viral lipid nanoparticle platform enables the delivery of a variety of payloads, and precise organ targeting of nucleic acid and protein payloads via both systemic and local delivery. ReCode is leveraging its nanoparticle and nucleic acid technologies across multiple modalities, including mRNA-mediated protein replacement therapies, first-in-class tRNA NanoCorrectors for diseases caused by nonsense mutations, and gene editing. The company was founded in 2015 and is based in Dallas, Texas.
Senti Biosciences is a clinical-stage biotechnology company based in South San Francisco, California, focused on developing innovative gene and cell therapies using its proprietary synthetic biology platform. Founded in 2016, the company aims to address complex diseases through advanced therapeutic solutions. Senti's technology includes engineered allogeneic chimeric antigen receptor natural killer (CAR-NK) cells, which are designed to target and eliminate cancer cells while minimizing damage to healthy tissue. Among its product candidates are SENTI-202, a Logic Gated CAR-NK cell therapy intended for cancer treatment, and SENTI-301A, which targets hepatocellular carcinoma. Senti Biosciences operates as a resident company at Johnson & Johnson Innovation's JLABS in South San Francisco, collaborating with experts in synthetic biology and computation to advance its therapeutic developments.
Senti Biosciences is a clinical-stage biotechnology company based in South San Francisco, California, focused on developing innovative gene and cell therapies using its proprietary synthetic biology platform. Founded in 2016, the company aims to address complex diseases through advanced therapeutic solutions. Senti's technology includes engineered allogeneic chimeric antigen receptor natural killer (CAR-NK) cells, which are designed to target and eliminate cancer cells while minimizing damage to healthy tissue. Among its product candidates are SENTI-202, a Logic Gated CAR-NK cell therapy intended for cancer treatment, and SENTI-301A, which targets hepatocellular carcinoma. Senti Biosciences operates as a resident company at Johnson & Johnson Innovation's JLABS in South San Francisco, collaborating with experts in synthetic biology and computation to advance its therapeutic developments.
9am.health redesigns all care elements into one digital service individualized around today’s reality of people’s life - always available and convenient, at prices anyone can afford even without insurance. 9am.health focuses on chronic conditions such as diabetes, hypertension, and hyperlipidemia for customers in the United States.
Apollo Agriculture is a company based in Nairobi, Kenya, that provides essential financial and technical support to smallholder farmers in emerging markets. Founded in 2015, it offers customized farming loans that enable farmers to purchase vital inputs such as seeds, fertilizers, and crop insurance. Utilizing agronomic machine learning, remote sensing, and mobile technology, Apollo assesses credit risk and tailors its services to each farmer's specific circumstances, enhancing their productivity and profitability. By leveraging satellite and soil data, along with insights into farmer behavior, Apollo aims to double farm yields and promote sustainable agricultural practices. The company's innovative approach combines technology with expert advice, positioning it as a key player in the agricultural sector.
Triumvira Immunologics is an immunotherapy company focused on developing innovative T cell therapies for cancer treatment. Founded in 2015 and headquartered in Austin, Texas, with research facilities in Hamilton, Canada, the company specializes in chimeric antigen receptor (CAR) and engineered T cell receptor (TCR) therapies. Its proprietary T cell Antigen Coupler (TAC) technology enhances the natural T cell receptor's capabilities and operates independently of the major histocompatibility complex. This unique approach aims to create more effective therapies for a diverse group of patients suffering from both solid and liquid tumors, as well as other diseases. Triumvira's commitment to advancing cancer treatment reflects its mission to improve patient outcomes with safer and more effective therapeutic options.
Woebot Health develops digital mental health solutions aimed at making mental health support widely accessible. Founded in 2017 and headquartered in San Francisco, the company utilizes chatbot technology to provide personalized support for mood-based disorders. Its platform integrates natural language processing with established therapeutic techniques, creating engaging interactions that deliver tailored responses to users facing specific mental health challenges. This innovative approach allows individuals to access effective mental health support conveniently, fitting seamlessly into their daily lives. Woebot Health is backed by several venture capital firms, emphasizing its commitment to advancing mental health care through technology.
Vivante Health, Inc. is a digital health company focused on addressing digestive health and chronic conditions. Founded in 2016, it has developed GIThrive, a technology platform designed to provide actionable insights for managing digestive issues. GIThrive offers a comprehensive digital gut health program that includes expert guidance, 24/7 support, and personalized care plans. The company also provides GIMate, an innovative portable breathalyzer that identifies trigger foods, and GutCheck, which analyzes gut bacteria to recommend tailored diets. Vivante Health emphasizes individualized care, utilizing a scalable platform that integrates real-time data from biometric devices and partners. This approach not only aims to reduce healthcare costs and improve employee health for large employers and health plans but also enhances user empowerment through advanced science and technology. Headquartered in Houston, Texas, with an additional office in Athens, Greece, Vivante Health continues to prioritize innovative solutions in the realm of digestive health.
Indapta Therapeutics is a privately held biotechnology company focused on developing a natural killer (NK) cell therapy platform aimed at treating both blood and solid tumor cancers. The company specializes in a proprietary off-the-shelf, non-engineered, and allogeneic G-NK cell designed to enhance the immune response and significantly improve the effectiveness of antibody therapies. Through its innovative approach, Indapta Therapeutics seeks to provide healthcare providers with advanced treatment options for patients suffering from cancer, leveraging the potent antibody-dependent cellular cytotoxicity (ADCC) activity of its NK cell therapy.
Dewpoint Therapeutics, Inc. is a Boston-based biotechnology company focused on the research and development of biomolecular condensates to create innovative treatments for a range of diseases, including cancer, neurodegenerative disorders, immunology, cardiovascular issues, women's health, and virology. Founded in 2018, the company utilizes a proprietary, AI-powered drug discovery platform that employs machine learning and advanced image analysis to visualize and manipulate biomolecular condensates. This technology aids in identifying novel drug candidates and has applications across various therapeutic areas. Dewpoint Therapeutics collaborates with leading academic and pharmaceutical partners to enhance its research and development efforts, aiming to deliver impactful healthcare solutions.
Gandeeva Therapeutics is a biotechnology company focused on drug discovery, utilizing a proprietary platform that integrates cryogenic electron microscopy and machine learning. This platform enables the detailed characterization of protein-drug interactions at the atomic level, facilitating insights into protein function and interactions. The company's approach includes target prediction and validation, hit identification through virtual and fragment library screening, and lead optimization. Gandeeva Therapeutics is developing innovative therapeutics aimed at key protein-protein interactions, particularly in oncology, with a robust preclinical pipeline that addresses challenging cancers using novel protein interaction modulators, such as interfacial glues and allosteric inhibitors. This methodology aims to reduce the risks associated with late-stage clinical failures in drug development.
Cellino Biotech, Inc. is a biotechnology company based in Cambridge, Massachusetts, founded in 2017. It specializes in intracellular delivery lasers and nanotechnology specifically for gene editing applications. The company has developed an AI-guided laser editing platform that automates the generation of personalized, autologous cell therapies, significantly reducing the development time of engineered cells from years to weeks. By integrating advanced tools from optics, biology, and computation, Cellino makes stem cell differentiation a digital process, allowing healthcare providers to efficiently produce functionally mature cells at scale. This innovative approach aims to enhance the accessibility of life-saving medicines for patients.
Metagenomi, Inc. is a genetic medicines company based in Emeryville, California, focused on developing innovative gene editing systems for the treatment of genetic diseases. Since its incorporation in 2016, the company has utilized a proprietary metagenomics-derived genome editing toolbox that enables the creation of curative therapeutics. This toolbox encompasses a range of advanced technologies, including programmable nucleases, base editors, and various RNA and DNA-mediated integration systems, such as prime editing systems and CRISPR-associated transposases (CASTs). Metagenomi aims to address the challenges posed by diverse mutations that have traditionally been difficult to target with existing genome engineering approaches.
Bloom Science, Inc. is a biotechnology company focused on developing neuroprotective medicines that leverage the microbiome to address epilepsy and other neurological disorders. Founded in 2017 and based in San Diego, California, the company aims to create genetically optimized microbes that can treat patients suffering from pharmacoresistant and underserved diseases. Bloom Science seeks to translate the therapeutic advantages of the ketogenic diet into innovative biopharmaceuticals, providing effective treatment options for individuals facing serious and life-altering neurological conditions.
MedArrive, Inc. is a New York-based startup that operates a software-as-a-service health platform designed to enhance home healthcare services. By connecting emergency medical services (EMS) professionals with patients, MedArrive enables healthcare providers to seamlessly extend care into patients' homes. The platform integrates physician-led telemedicine with hands-on support, facilitating effective communication and care management. This innovative approach allows for improved continuity of care, better patient outcomes, and cost savings for both patients and providers. Founded in 2020, MedArrive aims to bridge the virtual care gap, making high-quality healthcare more accessible to a broader population.
GRO Biosciences is leveraging breakthrough technologies from computational protein design and synthetic biology to develop best-in-class protein therapeutics with enhanced properties. The company has established multiple genomically recoded strains of bacteria that can incorporate non-standard amino acids into proteins to confer increased potency, stability, and targeted delivery. GRO Biosciences is applying its technology platform to develop improved protein therapeutics for diabetes, growth disorders and autoimmunity. The company, co-founded by Dr. George Church, is located at the Harvard Life Lab, a shared laboratory space for high-potential life sciences and biotechnology startups founded by Harvard faculty, alumni, students, and postdoctoral scholars.
Deka Biosciences
Series A in 2021
Early stage biotechnology start-up developing next generation cytokine therapeutics
Developer of disease-modifying therapies designed to focus on developing novel immune engagers. The company offers CD8 T-cell immune modulators for the treatment of autoimmune diseases as well as it specifically targets a subset of t-lymphocytes to delay the onset and ameliorate targeted autoimmune diseases, enabling doctors to administer state-of-the-art drugs for treating autoimmune disorders in patients.
Zerigo Health, formerly known as Clarify Medical, Inc., specializes in home therapy solutions for chronic skin conditions such as psoriasis, eczema, and vitiligo. The company offers innovative products like the Clarify mobile ultra violet B treatment system and the Home Light Therapy System, both designed to facilitate phototherapy in a home setting. Zerigo Health aims to enhance the ease and effectiveness of UVB therapy through a connected system that allows patients to manage their treatment via a smartphone app. This app enables users to control dosing, frequency, and duration of therapy, ensuring adherence to guidelines set by dermatology experts. By allowing patients to administer their treatments with clinical precision, Zerigo Health improves the overall patient experience, while also monitoring compliance and progress, ultimately empowering individuals to manage their chronic skin conditions more effectively from the comfort of their homes.
Developer of global soil cloud platform designed for sustainable agricultural management. The company's platform leverages advanced sensors and machine learning methods to build highly accurate soil maps from far fewer soil samples and facilitates mapping of a variety of soil attributes including soil compaction, fertility, and carbon levels, enabling farmers, ranchers, and land managers to make more profitable and sustainable soil management decisions for cultivation purpose.
Sound Agriculture Company develops innovative crop protection and enhancement products aimed at improving agricultural yields and farm revenues while addressing challenges such as drought. The company offers Source, a solution that enhances in-season nutrient uptake by unlocking existing nitrogen and phosphorus in the soil, thereby helping growers optimize crop performance sustainably. Additionally, Sound Agriculture focuses on improving photosynthesis, water capture, and crop efficiency, contributing to healthier and more flavorful food while reducing waste. Founded in 2012 and based in Emeryville, California, the company employs molecular discovery and life science approaches to create climate-resilient crops, ultimately enhancing productivity for farmers. Originally known as Asilomar Bio, Inc., it rebranded to Sound Agriculture Company in September 2018.
Andes Ag, Inc., founded in 2018 and headquartered in San Francisco, California, specializes in developing microbe-based seed technologies aimed at promoting sustainable agriculture. The company leverages beneficial microbes that have naturally co-evolved with plants over millennia. Through scientific research and advanced predictive software powered by artificial intelligence, Andes creates customized microbe-based formulations designed to enhance crop yields, accelerate growth, and enable cultivation in traditionally unsuitable lands. These solutions also aim to reduce the reliance on fertilizers and pesticides, helping farmers address the challenges posed by global climate change. Andes is positioned to contribute significantly to a new green revolution, fostering responsible and environmentally friendly agricultural practices.
Transcarent is a consumer digital health company, uses a combination of software, technology, and data science to empower consumers with information and access, leading to better outcomes and more cost-effective decisions. We believe that having the right information, tools, and incentives in the decision-making process can be positively transformative in the way we all experience healthcare.
Founded by Stuart Schreiber, Benjamin Cravatt, Stephanie Dougan, and Vasanthi Viswanathan, Kojin is accelerating a drug discovery platform that connects complex cell states to known biochemical processes such as ferroptosis, or iron-dependent cell death, and enables the development of selective therapies for a broad range of hard-to-treat diseases. The company’s investors include Polaris Partners, Newpath Partners, Cathay Health, Leaps by Bayer, AbbVie Inc., Eventide Asset Management, Alexandria, and the Dana-Farber Cancer Institute venture firm, Binney Street Capital.
Ada is a global health company founded by doctors, scientists, and industry pioneers to create new possibilities for personal health. Ada’s core system connects medical knowledge with intelligent technology to help all people actively manage their health and medical professionals to deliver effective care. Ada is proud to collaborate with leading health systems and global non-profit organizations to carry out this vision. The #1 medical app for 130 countries, almost 20 million assessments have been completed since its global launch in 2016.
Huma Therapeutics Limited is a healthcare technology company based in London, United Kingdom, focused on improving the lives of individuals with chronic, complex, and rare diseases. The company operates a healthcare platform that integrates patient data from various medical databases and devices, making it accessible to healthcare professionals. One of its key offerings is Medopad, a remote patient monitoring platform that allows doctors to oversee patients with conditions such as Covid-19 without the need for hospital admission. Huma collaborates with leading healthcare providers, pharmaceutical companies, insurers, and technology firms, including Apple and Tencent, to create a connected digital health ecosystem. Founded in 2011 and rebranded from Humaforhealth Limited in April 2020, Huma continues to expand its impact in the healthcare sector.
Edifice Health is a company that originated from a decade-long research study on immune profiling conducted at Stanford University. It has developed a biomarker composite scoring system that assesses individual immune health and determines the Inflammatory Age®, a measure that predicts the onset of various chronic diseases. The company focuses on improving methods for measuring systemic chronic inflammation, which is crucial for enhancing inflammatory and immune health. Edifice Health's innovative approach integrates applications in personalized nutritional and immunological science, leveraging AI-powered technology to aid healthcare professionals in the early detection of systemic chronic inflammation. This technology aims to provide comprehensive health insights that empower individuals to alter their aging trajectory and promote healthier aging.
Guardian Agriculture designs and manufactures unmanned aerial vehicles (UAVs) equipped with global positioning system (GPS) technology for agricultural applications. Founded in 2017 and based in Malden, Massachusetts, the company offers aerial crop protection and spray services, utilizing its UAVs to apply insecticides, herbicides, fungicides, and liquid fertilizers. By leveraging advanced technology, Guardian Agriculture aims to enhance crop protection and improve agricultural efficiency.
Pyxis Oncology, Inc. is a biotechnology company focused on developing antibody therapeutics that enhance the immune response against cancer. Founded in 2018 and based in Boston, Massachusetts, the company specializes in analyzing tumor antigen-specific tumor-infiltrating lymphocytes within hot tumors and tumor cell signaling pathways in cold tumors. This research informs the creation of novel antibody-based immunotherapies aimed at targeting difficult-to-treat cancers. Pyxis Oncology's goal is to develop next-generation therapeutics that not only kill tumor cells but also address the underlying issues that facilitate cancer's proliferation and immune evasion, ultimately improving the quality of life for patients.
Century Therapeutics, Inc. is a biotechnology company focused on developing induced pluripotent stem cell (iPSC)-based therapies for cancer treatment. Founded in 2018 and headquartered in Philadelphia, Pennsylvania, the company aims to create allogeneic living drugs that specifically target both hematologic and solid tumors. By utilizing iPSCs, Century Therapeutics can engineer immune effector cells through multiple rounds of cellular modification, producing master cell banks that can be expanded and differentiated for therapeutic use. Their innovative approach incorporates advanced technologies such as CRISPR-mediated gene editing and proprietary chimeric antigen receptors, along with Allo-Evasion technology, which helps prevent rejection by the host immune system. These advancements position Century Therapeutics to enhance the effectiveness and accessibility of cancer treatments.
EGenesis Inc. is a biotechnology company based in Cambridge, Massachusetts, with an additional office in New York. Founded in 2015, the company specializes in gene editing and genome engineering, focusing on the development of human-compatible organs, tissues, and cells for transplantation. EGenesis employs advanced gene editing techniques to create transplantable cells and solid organs, specifically targeting therapeutic applications in kidney and islet cell transplantation. By leveraging its innovative platform, the company aims to transform the field of organ transplantation, providing safe and effective solutions for patients with life-threatening diseases globally.
Grão Direto LTDA operates a digital trading platform designed for the buying and selling of grains, facilitating interactions between farmers and grain buyers. Founded in 2016 and based in Uberaba, Brazil, the platform enhances market intelligence analysis, enabling users to make informed decisions regarding market rates and grain selection. It supports various trading types, including spot, future, and barter trades, while also streamlining associated processes such as logistics, contract management, and financial products. Grão Direto connects a diverse range of participants in the agricultural sector, including cooperatives, brokers, feed factories, and traders, promoting efficiency and agility in the grain trading process through modern technology.
Amfora is an emerging leader in the use of biotechnology to address the rapidly growing global demand for protein. Amfora is working to develop nutritionally enhanced forage crops for a market expected to have an annual value of as much as $12 billion a year. The company is based in San Francisco, California and is a portfolio company of Spruce Capital Partners LLC/MLS II Fund.
Pairwise is a food and technology company focused on enhancing the quality and appeal of fruits and vegetables through advanced gene-editing techniques. Founded in 2017 by a team of experts from diverse fields, Pairwise aims to create healthier and more convenient produce by developing new varieties of leafy greens, berries, and stone fruits. The company holds licenses for innovative gene-editing tools and is building an internal portfolio of traits designed to improve taste, texture, and nutritional value while also addressing environmental concerns. With a commitment to transforming dietary habits and reducing food waste, Pairwise collaborates with food and agriculture companies to deliver differentiated products that meet evolving consumer demands. The company is headquartered in San Diego, California.
Developer of immunity-boosting proteins designed to improve the lives of people who suffer from food allergies and gluten-related disorders. The company's technology uses artificial intelligence, immunology, computational biology, and protein engineering to make safe proteins that do not trigger an immune response, enabling physicians to prescribe to people products that are safe to consume.
Senti Biosciences is a clinical-stage biotechnology company based in South San Francisco, California, focused on developing innovative gene and cell therapies using its proprietary synthetic biology platform. Founded in 2016, the company aims to address complex diseases through advanced therapeutic solutions. Senti's technology includes engineered allogeneic chimeric antigen receptor natural killer (CAR-NK) cells, which are designed to target and eliminate cancer cells while minimizing damage to healthy tissue. Among its product candidates are SENTI-202, a Logic Gated CAR-NK cell therapy intended for cancer treatment, and SENTI-301A, which targets hepatocellular carcinoma. Senti Biosciences operates as a resident company at Johnson & Johnson Innovation's JLABS in South San Francisco, collaborating with experts in synthetic biology and computation to advance its therapeutic developments.
Rantizo, Inc. is a company based in Iowa City, Iowa, that specializes in the development and sale of agricultural drones and related equipment. Founded in 2018, Rantizo offers a range of products, including trailers, drone sprayers, spreaders, battery chargers, and batteries. The company provides spraying services for crops using an innovative electrostatic spraying technology that ensures uniform coverage, allowing farmers to apply pesticides and chemicals efficiently and effectively. Rantizo's system is designed to integrate with various drone manufacturers and agronomy systems, addressing key challenges in large-scale agriculture. By delivering targeted liquid and dry applications precisely when and where needed, Rantizo enables farmers to optimize their operations and improve productivity in the field.
Metagenomi, Inc. is a genetic medicines company based in Emeryville, California, focused on developing innovative gene editing systems for the treatment of genetic diseases. Since its incorporation in 2016, the company has utilized a proprietary metagenomics-derived genome editing toolbox that enables the creation of curative therapeutics. This toolbox encompasses a range of advanced technologies, including programmable nucleases, base editors, and various RNA and DNA-mediated integration systems, such as prime editing systems and CRISPR-associated transposases (CASTs). Metagenomi aims to address the challenges posed by diverse mutations that have traditionally been difficult to target with existing genome engineering approaches.
Azitra Inc. is a clinical-stage medical dermatology company based in Farmington, Connecticut, focused on developing microbiome-based therapeutics for skin diseases. Established in 2014, Azitra leverages its proprietary platform, which includes a microbial library of bacterial strains, to discover and create novel treatments for adverse skin conditions. The company's technology, developed in collaboration with researchers at Yale University and the Jackson Laboratory, is centered around a specific strain of the natural commensal bacteria Staphylococcus epidermidis. Additionally, Azitra employs artificial intelligence and machine learning to enhance the screening and prediction of therapeutic characteristics within its microbial library. By utilizing engineered proteins and live biotherapeutic products for topical application, Azitra aims to advance precision dermatology.
Dewpoint Therapeutics, Inc. is a Boston-based biotechnology company focused on the research and development of biomolecular condensates to create innovative treatments for a range of diseases, including cancer, neurodegenerative disorders, immunology, cardiovascular issues, women's health, and virology. Founded in 2018, the company utilizes a proprietary, AI-powered drug discovery platform that employs machine learning and advanced image analysis to visualize and manipulate biomolecular condensates. This technology aids in identifying novel drug candidates and has applications across various therapeutic areas. Dewpoint Therapeutics collaborates with leading academic and pharmaceutical partners to enhance its research and development efforts, aiming to deliver impactful healthcare solutions.
Recursion Pharmaceuticals is a clinical-stage biotechnology company based in Salt Lake City, Utah, founded in 2013. The company utilizes artificial intelligence, automation, and experimental biology to streamline drug discovery and develop treatments for various diseases modeled at the cellular level. Its innovative platform includes multiple software solutions such as ReChem for chemical compound design, ReScreen for managing complex experiments, and RePredict, which employs machine learning to analyze drug compound relationships. Initially focused on drug repurposing for rare diseases, Recursion has expanded its research to address a wider range of conditions, including aging, inflammation, infectious diseases, and immunology. By leveraging advanced technology and high-throughput automated screening, Recursion Pharmaceuticals aims to create a comprehensive understanding of human cellular biology, significantly enhancing the efficiency and effectiveness of discovering new treatments.
Triumvira Immunologics is an immunotherapy company focused on developing innovative T cell therapies for cancer treatment. Founded in 2015 and headquartered in Austin, Texas, with research facilities in Hamilton, Canada, the company specializes in chimeric antigen receptor (CAR) and engineered T cell receptor (TCR) therapies. Its proprietary T cell Antigen Coupler (TAC) technology enhances the natural T cell receptor's capabilities and operates independently of the major histocompatibility complex. This unique approach aims to create more effective therapies for a diverse group of patients suffering from both solid and liquid tumors, as well as other diseases. Triumvira's commitment to advancing cancer treatment reflects its mission to improve patient outcomes with safer and more effective therapeutic options.
Unfold Bio, Inc. specializes in developing seeds for indoor vertical farming, offering varieties such as lettuce, spinach, cucumbers, tomatoes, and peppers. Founded in 2020 and based in Sacramento, California, the company utilizes advanced seed genetics and agronomic expertise to enhance productivity and flavor, catering to the growing vertical farming market. Its innovative approach allows for optimal water use, minimizes reliance on synthetic inputs, and facilitates food production in environments with limited arable land. Unfold collaborates with vertical farming operators, technology providers, and stakeholders across the produce supply chain to foster a sustainable local food culture. The company also conducts research and development operations in California and Singapore, aiming to improve food variety and consumer experiences in the industry.
Vesigen, Inc. is a biotechnology company focused on developing innovative therapeutic products that utilize extracellular vesicle delivery technology to target intracellular sites. Founded in 2020 and based in Cambridge, Massachusetts, the company employs its proprietary ARMMs technology to facilitate the direct delivery of various payloads, including RNAs, proteins, and gene-editing complexes, into the cytoplasm of target cells. This approach aims to overcome the challenges associated with intracellular drug delivery, thereby broadening the range of potential druggable targets and enabling the creation of novel treatments for various diseases. Vesigen's mission is to address unmet medical needs through its advanced therapeutic solutions.
Apollo Agriculture is a company based in Nairobi, Kenya, that provides essential financial and technical support to smallholder farmers in emerging markets. Founded in 2015, it offers customized farming loans that enable farmers to purchase vital inputs such as seeds, fertilizers, and crop insurance. Utilizing agronomic machine learning, remote sensing, and mobile technology, Apollo assesses credit risk and tailors its services to each farmer's specific circumstances, enhancing their productivity and profitability. By leveraging satellite and soil data, along with insights into farmer behavior, Apollo aims to double farm yields and promote sustainable agricultural practices. The company's innovative approach combines technology with expert advice, positioning it as a key player in the agricultural sector.
CoverCress is a biotechnology company that focuses on research and development of renewable fuel and livestock feed. It specializes in producing an oilseed crop for food, bioenergy, and cattle feed. It specializes in the fields of agriculture, biotechnology, plants, genetics, cover crop, and precision agriculture. CoverCress was founded in 2013 by Jerry Steiner and Dr. Tim Ulmasov and is headquartered in St. Louis Missouri.
NewLeaf Symbiotics, Inc. is a research-driven company based in Saint Louis, Missouri, specializing in the development and commercialization of beneficial symbiotic bacteria to enhance plant health and increase crop yields. The company focuses on Pink Pigmented Facultative Methylotrophs (PPFMs), which are natural bacteria beneficial to various agricultural sectors, including row crops, vegetables, fruits, and flowers. NewLeaf conducts extensive laboratory, greenhouse, and field trials to validate and refine its products, which are designed to help farmers combat plant diseases sustainably. Established in 2011 and previously known as TrophoMax, NewLeaf aims to innovate and expand its offerings through ongoing research and the filing of related patents, with the goal of commercializing its products.
Pyxis Oncology, Inc. is a biotechnology company focused on developing antibody therapeutics that enhance the immune response against cancer. Founded in 2018 and based in Boston, Massachusetts, the company specializes in analyzing tumor antigen-specific tumor-infiltrating lymphocytes within hot tumors and tumor cell signaling pathways in cold tumors. This research informs the creation of novel antibody-based immunotherapies aimed at targeting difficult-to-treat cancers. Pyxis Oncology's goal is to develop next-generation therapeutics that not only kill tumor cells but also address the underlying issues that facilitate cancer's proliferation and immune evasion, ultimately improving the quality of life for patients.
Century Therapeutics, Inc. is a biotechnology company focused on developing induced pluripotent stem cell (iPSC)-based therapies for cancer treatment. Founded in 2018 and headquartered in Philadelphia, Pennsylvania, the company aims to create allogeneic living drugs that specifically target both hematologic and solid tumors. By utilizing iPSCs, Century Therapeutics can engineer immune effector cells through multiple rounds of cellular modification, producing master cell banks that can be expanded and differentiated for therapeutic use. Their innovative approach incorporates advanced technologies such as CRISPR-mediated gene editing and proprietary chimeric antigen receptors, along with Allo-Evasion technology, which helps prevent rejection by the host immune system. These advancements position Century Therapeutics to enhance the effectiveness and accessibility of cancer treatments.
Dewpoint Therapeutics, Inc. is a Boston-based biotechnology company focused on the research and development of biomolecular condensates to create innovative treatments for a range of diseases, including cancer, neurodegenerative disorders, immunology, cardiovascular issues, women's health, and virology. Founded in 2018, the company utilizes a proprietary, AI-powered drug discovery platform that employs machine learning and advanced image analysis to visualize and manipulate biomolecular condensates. This technology aids in identifying novel drug candidates and has applications across various therapeutic areas. Dewpoint Therapeutics collaborates with leading academic and pharmaceutical partners to enhance its research and development efforts, aiming to deliver impactful healthcare solutions.